Late last year, the drug chalked up a medical first when it became the first drug to delay the onset of bonemetastases in high-risk prostate cancer patients who were failing hormone therapy.
But Harper says the way the trial was designed, it would have been nearly impossible to show a survival difference, as patients immediately went on another approved bone drug as soon as the developed metastases.